Published in
Taylor and Francis Group, OncoImmunology, 3(2), p. e23431
DOI: 10.4161/onci.23431
Links
- ORCID
- Taylor and Francis Group | PDF
- [www.ncbi.nlm.nih.gov] | PDF
- [europepmc.org] | PDF
- [www.researchgate.net] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
Tools
Naturally circulating dendritic cells to vaccinate cancer patients
Journal article published in 2013 by
Kalijn F. Bol 
,
Jurjen Tel,
I. Jolanda M. de Vries,
I. Jolanda M. de Vries,
Carl G. Figdor
,
Jurjen Tel,
I. Jolanda M. de Vries,
I. Jolanda M. de Vries,
Carl G. Figdor
This paper is made freely available by the publisher.
Full text: Download
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 
Abstract
Dendritic cell-based immunotherapy is a promising strategy against cancer that appears to be feasible, safe and to induce potent tumor-specific immune responses. The use of naturally circulating dendritic cells (DCs), rather than cultured monocyte-derived DCs, might constitute the next logical step to translate anticancer immune responses into long-lasting clinical benefits.